IS2599B - 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess - Google Patents

3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess

Info

Publication number: IS2599B
Authority: IS; Iceland
Prior art keywords: phenylsulfonyl; piperazin; quinoline; pharmaceutically acceptable; acceptable derivatives
Prior art date: 2002-03-27

Application number

IS7470A

Other languages

English (en)

Other versions

IS7470A (is

Inventor

Mahmood Ahmed

Christopher Norbert Johnson

Martin C Jones

Gregor James Macdonald

Stephen Frederick Moss

Mervyn Thompson

Charles Edward Wade

David Witty

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-27

Filing date

2004-09-24

Publication date

2010-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28456035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2599(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-03-27 Priority claimed from GB0207289A external-priority patent/GB0207289D0/en

2002-11-04 Priority claimed from GB0225678A external-priority patent/GB0225678D0/en

2004-09-24 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2004-09-24 Publication of IS7470A publication Critical patent/IS7470A/is

2010-04-15 Publication of IS2599B publication Critical patent/IS2599B/is

Links

JJZFWROHYSMCMU-UHFFFAOYSA-N 3-(benzenesulfonyl)-8-piperazin-1-ylquinoline Chemical compound C=1N=C2C(N3CCNCC3)=CC=CC2=CC=1S(=O)(=O)C1=CC=CC=C1 JJZFWROHYSMCMU-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

IS7470A 2002-03-27 2004-09-24 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess IS2599B (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0207289A GB0207289D0 (en)	2002-03-27	2002-03-27	Novel compounds
GB0225678A GB0225678D0 (en)	2002-11-04	2002-11-04	Novel compounds
PCT/EP2003/003197 WO2003080580A2 (en)	2002-03-27	2003-03-25	Quinoline derivatives and their use as 5-ht6 ligands

Publications (2)

Publication Number	Publication Date
IS7470A IS7470A (is)	2004-09-24
IS2599B true IS2599B (is)	2010-04-15

Family

ID=28456035

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7470A IS2599B (is)	2002-03-27	2004-09-24	3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess

Country Status (27)

Country	Link
US (5)	US7452888B2 (is)
EP (2)	EP1497266B1 (is)
JP (2)	JP4455064B2 (is)
KR (1)	KR101020399B1 (is)
CN (1)	CN1315809C (is)
AR (1)	AR039127A1 (is)
AT (1)	ATE398108T1 (is)
AU (1)	AU2003219103B2 (is)
BR (1)	BRPI0308696B8 (is)
CA (1)	CA2479786C (is)
CY (2)	CY1108313T1 (is)
DE (1)	DE60321558D1 (is)
DK (2)	DK1497266T3 (is)
ES (2)	ES2386828T3 (is)
IL (2)	IL164108A0 (is)
IS (1)	IS2599B (is)
MX (1)	MXPA04009318A (is)
MY (1)	MY138836A (is)
NO (1)	NO329319B1 (is)
NZ (1)	NZ535239A (is)
PL (1)	PL209872B1 (is)
PT (2)	PT1956004E (is)
RU (1)	RU2309154C9 (is)
SI (2)	SI1497266T1 (is)
TW (1)	TWI268928B (is)
WO (1)	WO2003080580A2 (is)
ZA (1)	ZA200407320B (is)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2386828T3 (es) *	2002-03-27	2012-08-31	Glaxo Group Limited	Derivados de quinolina y su uso como ligandos 5-HT6
BRPI0407253A (pt)	2003-02-14	2006-01-31	Wyeth Corp	Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
AU2004213375A1 (en)	2003-02-14	2004-09-02	Wyeth	Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-Hydroxytryptamine-6 ligands
US8754238B2 (en)	2003-07-22	2014-06-17	Arena Pharmaceuticals, Inc.	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
GB0320320D0 (en) *	2003-08-29	2003-10-01	Glaxo Group Ltd	Novel compounds
GB0321473D0 (en) *	2003-09-12	2003-10-15	Glaxo Group Ltd	Novel compounds
GB0322510D0 (en)	2003-09-25	2003-10-29	Glaxo Group Ltd	Novel compounds
PT1667975E (pt) *	2003-09-26	2008-02-29	Glaxo Group Ltd	Forma polimórfica de 3-fenilsulfonil-8-piperazin-1-il-quinolina
GB0407025D0 (en) *	2004-03-29	2004-04-28	Glaxo Group Ltd	Novel compounds
GB0411421D0 (en) *	2004-05-21	2004-06-23	Glaxo Group Ltd	Novel compounds
GB0425548D0 (en) *	2004-11-19	2004-12-22	Glaxo Group Ltd	Radiolabelled ligands
GB0426313D0 (en) *	2004-12-01	2005-01-05	Merck Sharp & Dohme	Therapeutic agents
MX2007014929A (es)	2005-06-02	2008-02-15	Hoffmann La Roche	3-metansulfonilquinolinas como mejoradores de gaba-b.
KR20080030058A (ko)	2005-07-27	2008-04-03	에프. 호프만-라 로슈 아게	5-ｈｔ6 조절인자로서 4-아릴옥시 퀴놀린 유도체
GB0519760D0 (en) *	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds
GB0519758D0 (en) *	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel process
GB0519765D0 (en) *	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds
EA200801525A1 (ru) *	2005-12-20	2008-10-30	Рихтер Гедеон Нирт.	ПРОИЗВОДНЫЕ ХИНОЛИНА, ПРИМЕНИМЫЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ РЕЦЕПТОРАМИ mGluR5
EP2001865A1 (en)	2006-04-05	2008-12-17	Wyeth a Corporation of the State of Delaware	Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
ES2357584T3 (es)	2007-01-08	2011-04-27	Suven Life Sciences Limited	Compuestos de 5-(heterociclil) alquil-n-(arilsulfonil)indol y su uso como ligandos de 5-th6.
JP5550352B2 (ja) *	2007-03-15	2014-07-16	ノバルティスアーゲー	有機化合物およびその使用
WO2008113818A1 (en) *	2007-03-21	2008-09-25	Glaxo Group Limited	Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
ES2373617T3 (es)	2007-03-23	2012-02-07	Abbott Gmbh & Co. Kg	Compuestos de quinolina adecuados para tratar trastornos que responden a la modulación del receptor 5-ht6 de serotonina.
EA016594B1 (ru)	2007-05-03	2012-06-29	Сувен Лайф Сайенсиз Лимитед	Производные 1-(аминоалкоксиарилсульфонил)индола в качестве 5-нтлигандов
JP5543917B2 (ja) *	2007-06-18	2014-07-09	リヒターゲデオンニルバーノシャンミーケデーレスベニュタールシャシャーグ	スルホニル−キノリン誘導体
ES2574154T3 (es) *	2007-08-07	2016-06-15	Abbvie Deutschland Gmbh & Co Kg	Compuestos de quinolina adecuados para tratar trastornos que responden a la modulación del receptor de serotonina 5-HT6
CA2703157C (en)	2007-10-26	2013-02-05	Suven Life Sciences Limited	Amino arylsulfonamide compounds and their use as 5-ht6 ligands
US9084742B2 (en) *	2007-12-12	2015-07-21	Axovant Sciences Ltd.	Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
BRPI0908807A2 (pt) *	2008-02-15	2015-07-28	Hoffmann La Roche	Derivados de 3-alquil-piperazina e usos dos mesmos
US20110021538A1 (en)	2008-04-02	2011-01-27	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20100041663A1 (en)	2008-07-18	2010-02-18	Novartis Ag	Organic Compounds as Smo Inhibitors
US8318725B2 (en)	2008-09-17	2012-11-27	Suven Life Sciences Limited	Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
WO2010032258A1 (en)	2008-09-17	2010-03-25	Suven Life Sciences Limited	Aryl sulfonamide amine compounds and their use as 5-ht6 ligands
WO2010062321A1 (en)	2008-10-28	2010-06-03	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
CR20170071A (es)	2009-06-29	2017-03-28	Agios Pharmaceuticals Inc	Compuestos terapeuticos y composiciones
AP3294A (en) *	2010-01-04	2015-05-31	Nippon Soda Co	Nitrogen-containing heterocyclic compound and agricultural fungicide
KR101463190B1 (ko)	2010-01-05	2014-11-18	수벤 라이프 사이언시스 리미티드	５ｈｔ６ 수용체 리간드인 술폰 화합물
RU2443697C1 (ru) *	2010-12-21	2012-02-27	Александр Васильевич Иващенко	Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения
KR101250606B1 (ko) *	2011-01-24	2013-04-03	이화여자대학교 산학협력단	5-ｈｔ６ 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
AR086411A1 (es)	2011-05-20	2013-12-11	Nippon Soda Co	Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
EP2763676B1 (en)	2011-10-03	2019-12-25	The University of Utah Research Foundation	Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
RU2500672C1 (ru) *	2012-10-25	2013-12-10	Андрей Александрович Иващенко	(3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения
US9302992B2 (en)	2013-04-02	2016-04-05	Annji Pharmaceutical Co., Ltd.	Multifunctional quinoline derivatives as anti-neurodegenerative agents
KR101802048B1 (ko)	2013-04-02	2017-12-28	안지 파마슈티컬 코퍼레이션 리미티드	항신경퇴행성제로서의 다작용성 퀴놀린 유도체
WO2016179566A1 (en) *	2015-05-07	2016-11-10	Axovant Sciences Ltd.	Methods of treating a neurodegenerative disease
RU2017145976A (ru)	2015-06-12	2019-07-15	Аксовант Сайенсиз Гмбх	Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
TW201720439A (zh)	2015-07-15	2017-06-16	Axovant Sciences Gmbh	用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
AR106515A1 (es) *	2015-10-29	2018-01-24	Bayer Cropscience Ag	Sililfenoxiheterociclos trisustituidos y análogos
CN109069450A (zh) *	2016-02-05	2018-12-21	法奈克斯公司	神经障碍的新的组合疗法
US10160744B2 (en)	2016-03-14	2018-12-25	AbbVie Deutschland GmbH & Co. KG	Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor
WO2017202206A1 (zh) *	2016-05-27	2017-11-30	深圳市塔吉瑞生物医药有限公司	一种取代的喹啉化合物及其药物组合物
WO2018102824A1 (en) *	2016-12-02	2018-06-07	Axovant Sciences Gmbh	Methods for treating neurodegenerative disease
KR20210076224A (ko)	2019-12-13	2021-06-24	주식회사 에피바이오텍	퀴놀린 유도체를 포함하는 탈모의 예방 또는 치료용 조성물
KR102281647B1 (ko) *	2020-12-09	2021-07-30	메디케어제약 주식회사	피페라진-퀴놀린 유도체의 제조방법

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US708469A (en) *	1901-08-27	1902-09-02	George Lafayette Caldwell	Stroke-regulating mechanism for glass-presses, &c.
JPH02262627A (ja)	1988-12-08	1990-10-25	Japan Synthetic Rubber Co Ltd	有機非線形光学素子
SI9200377A (en) *	1992-12-11	1994-06-30	Krka	Process for the preparation of 1-substituted 6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydroquinoline-3-carboxilic acid, novel intermediate used in this process and process for its preparation
GB9300147D0 (en)	1993-01-06	1993-03-03	Minnesota Mining & Mfg	Photothermographic materials
GB9311790D0 (en)	1993-06-08	1993-07-28	Minnesota Mining & Mfg	Photothermographic materials
US5596001A (en)	1993-10-25	1997-01-21	Pfizer Inc.	4-aryl-3-(heteroarylureido)quinoline derivatves
DK122693D0 (da)	1993-10-29	1993-10-29	Hempels Skibsfarve Fab J C	Marin struktur
US5576338A (en)	1995-02-15	1996-11-19	Merck Frosst Canada, Inc.	Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
AUPN842196A0 (en)	1996-03-05	1996-03-28	Fujisawa Pharmaceutical Co., Ltd.	New compound
FR2750988B1 (fr)	1996-07-11	1998-09-18	Adir	Nouveaux derives de 2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DZ2376A1 (fr)	1996-12-19	2002-12-28	Smithkline Beecham Plc	Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
US20010051719A1 (en)	1996-12-19	2001-12-13	Smithkline Beecham P.L.C.	Novel compounds
DE59803962D1 (de)	1997-03-25	2002-06-06	Ciba Sc Holding Ag	Polycyclische Verbindungen
ATE250035T1 (de)	1997-04-22	2003-10-15	Janssen Pharmaceutica Nv	Chinolin- und chinazolin-derivate als crf antagonisten
AU747026B2 (en)	1997-05-28	2002-05-09	Aventis Pharmaceuticals Inc.	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
CA2293418A1 (en)	1997-06-19	1998-12-23	Michael Z. Hoemann	Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6103905A (en)	1997-06-19	2000-08-15	Sepracor, Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6376670B1 (en)	1997-06-19	2002-04-23	Sepracor Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6207679B1 (en)	1997-06-19	2001-03-27	Sepracor, Inc.	Antimicrobial agents uses and compositions related thereto
JP2002511097A (ja)	1997-07-11	2002-04-09	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	５−ｈｔ▲下６▼レセプターアンタゴニストであるスルホンアミド誘導体およびその製造方法
EP0930302B1 (en) *	1998-01-16	2003-04-02	F.Hoffmann-La Roche Ag	Benzosulfone derivatives
GB9801392D0 (en)	1998-01-22	1998-03-18	Smithkline Beecham Plc	Novel compounds
GB9803411D0 (en)	1998-02-18	1998-04-15	Smithkline Beecham Plc	Novel compounds
US6100291A (en)	1998-03-16	2000-08-08	Allelix Biopharmaceuticals Inc.	Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) *	1998-06-15	2001-06-26	Nps Allelix Corp.	Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9818916D0 (en)	1998-08-28	1998-10-21	Smithkline Beecham Plc	Use
GB9819382D0 (en)	1998-09-04	1998-10-28	Cerebrus Ltd	Chemical compounds I
GB9820113D0 (en)	1998-09-15	1998-11-11	Merck Sharp & Dohme	Therapeutic agents
US6403808B1 (en)	1999-12-10	2002-06-11	Virginia Commonwealth University	Selective 5-HT6 receptor ligands
WO2000042026A1 (en)	1999-01-15	2000-07-20	Novo Nordisk A/S	Non-peptide glp-1 agonists
EP1165542B1 (en)	1999-03-29	2003-08-20	Neurogen Corporation	4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
ATE375990T1 (de) *	1999-04-21	2007-11-15	Nps Allelix Corp	Piperidin-indol derivate mit 5-ht6 affinität
AU4802500A (en)	1999-04-26	2000-11-10	Neurogen Corporation	2-aminoquinolinecarboxamides: neurokinin receptor ligands
US6566372B1 (en)	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
MY125942A (en)	1999-09-07	2006-09-29	Upjohn Co	Aminoalkoxy carbazoles for the treatment of cns diseases
AU1542201A (en)	1999-11-05	2001-05-14	Nps Allelix Corp.	Compounds having 5-HT6 receptor antagonist activity
GB9926302D0 (en) *	1999-11-05	2000-01-12	Smithkline Beecham Plc	Novel compounds
UA75055C2 (uk)	1999-11-30	2006-03-15	Пфайзер Продактс Інк.	Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6310212B1 (en)	2000-03-28	2001-10-30	Neurogen Corporation	4-substituted quinoline derivatives
PE20020063A1 (es)	2000-06-20	2002-01-30	Upjohn Co	Bis-arilsulfonas como ligandos del receptor de 5-ht
SE0002754D0 (sv)	2000-07-21	2000-07-21	Pharmacia & Upjohn Ab	New pharmaceutical combination formulation and method of treatment with the combination
GB0021450D0 (en)	2000-08-31	2000-10-18	Smithkline Beecham Plc	Novel compounds
US6576644B2 (en)	2000-09-06	2003-06-10	Bristol-Myers Squibb Co.	Quinoline inhibitors of cGMP phosphodiesterase
SK5212003A3 (en)	2000-10-02	2004-03-02	Janssen Pharmaceutica Nv	Metabotropic glutamate receptor antagonists
KR100823908B1 (ko)	2000-10-20	2008-04-21	바이오비트럼 에이비(피유비엘)	2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
EP2298738B1 (en)	2000-11-02	2012-09-19	Wyeth LLC	1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
AU2002215047A1 (en)	2000-11-21	2002-06-03	Smithkline Beecham Plc	Isoquinoline derivatives useful in the treatment of cns disorders
WO2002041889A2 (en)	2000-11-24	2002-05-30	Smithkline Beecham P.L.C.	Indolsulfonyl compounds useful in the treatment of cns disorders
ES2188344B1 (es)	2000-11-29	2004-09-16	Laboratorios Vita, S.A.	Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
GB0111186D0 (en)	2001-05-08	2001-06-27	Smithkline Beecham Plc	Novel compounds
JP4187642B2 (ja)	2001-06-07	2008-11-26	エフ．ホフマン−ラロシュアーゲー	５−ｈｔ６受容体親和性を有する新規インドール誘導体
ES2268113T3 (es)	2001-06-15	2007-03-16	F. Hoffmann-La Roche Ag	Derivados de 4-piperazinilindol con afinidad al receptor 5-ht6.
ITRM20010356A1 (it)	2001-06-21	2002-12-23	Sigma Tau Ind Farmaceuti	"5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
EP1411925A1 (en)	2001-08-03	2004-04-28	PHARMACIA & UPJOHN COMPANY	5-arylsulfonyl indoles having 5-ht6 receptor affinity
JP2005527463A (ja)	2001-08-07	2005-09-15	スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー	Ｃｎｓ疾患を治療するための５−ｈｔ６受容体アフィニティーを有する３−アリールスルホニル−７−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン
MXPA04001250A (es)	2001-08-10	2004-05-27	Hoffmann La Roche	Derivados de arilsulfonilo con afinidad receptora de 5-hidroxitriptamina6 (5-ht6).
DK2305656T3 (da)	2001-08-31	2013-02-11	Novartis Ag	Optiske isomerer of en iloperidonmetabolit
SE0103649D0 (sv)	2001-11-01	2001-11-01	Astrazeneca Ab	Therapeutic quinoline compounds
WO2003062205A1 (en)	2001-12-21	2003-07-31	Smithkline Beecham P.L.C.	7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
US20070270432A1 (en)	2002-02-05	2007-11-22	James Hagan	Novel Method
GB0202679D0 (en)	2002-02-05	2002-03-20	Glaxo Group Ltd	Novel compounds
US20050090485A1 (en)	2002-02-13	2005-04-28	Bromidge Steven M.	7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders
DE10207844A1 (de)	2002-02-15	2003-09-04	Schering Ag	1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
US20030220325A1 (en)	2002-02-22	2003-11-27	Tenbrink Ruth E.	Arylsulfone derivatives
ES2386828T3 (es) *	2002-03-27	2012-08-31	Glaxo Group Limited	Derivados de quinolina y su uso como ligandos 5-HT6
US20050124626A1 (en)	2002-03-27	2005-06-09	Johnson Christopher N.	Novel compounds
KR100636475B1 (ko)	2002-05-13	2006-10-18	에프. 호프만-라 로슈 아게	5-ｈｔ6 조절제로서 벤족사진 유도체 및 이의 용도
DE10221183A1 (de)	2002-05-13	2003-12-04	Max Planck Gesellschaft	Phosphatidyl-oligo-glycerine und Strukturanaloga
CN1293053C (zh)	2002-06-05	2007-01-03	弗·哈夫曼-拉罗切有限公司	作为5－ht6－受体调节剂用于治疗cns－病症的1－磺酰基－4－氨基烷氧基吲哚衍生物
US7943639B2 (en)	2002-06-20	2011-05-17	Proximagen Limited	Compounds
NZ552282A (en)	2002-06-20	2008-07-31	Biovitrum Ab Publ	New compounds useful for the treatment of obesity, type II diabetes and CNS disorders
WO2004026831A1 (en)	2002-09-17	2004-04-01	F. Hoffmann-La Roche Ag	2,4-substituted indoles and their use as 5-ht6 modulators
JP4327091B2 (ja)	2002-09-17	2009-09-09	エフ．ホフマン−ラロシュアーゲー	２，７−置換インドール及び５−ｈｔ６モジュレーターとしてのその使用
WO2004035047A1 (en)	2002-10-18	2004-04-29	F. Hoffmann-La Roche Ag	4-piperazinyl benzenesulfonyl indoles with 5-ht6 receptor affinity
PT1562918E (pt)	2002-11-08	2008-03-12	Hoffmann La Roche	Benzoxazinonas substituídas e as suas utilizações
ES2291722T3 (es)	2002-12-03	2008-03-01	Hoffmann La Roche	Aminoalcoxiindoles como ligandos 5-ht6-receptores para el tratamiento de transtornos del snc.
AU2004213375A1 (en)	2003-02-14	2004-09-02	Wyeth	Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-Hydroxytryptamine-6 ligands
CN100395237C (zh)	2003-03-03	2008-06-18	弗·哈夫曼-拉罗切有限公司	用作5－ht6调节剂的2,5－取代的四氢异喹啉
TWI289141B (en)	2003-03-11	2007-11-01	Hoffmann La Roche F. Ag.	Quinolinone derivatives and uses thereof
GB0305575D0 (en)	2003-03-11	2003-04-16	Glaxo Group Ltd	Novel compounds
GB0320320D0 (en)	2003-08-29	2003-10-01	Glaxo Group Ltd	Novel compounds
GB0321473D0 (en)	2003-09-12	2003-10-15	Glaxo Group Ltd	Novel compounds
GB0322510D0 (en)	2003-09-25	2003-10-29	Glaxo Group Ltd	Novel compounds
PT1667975E (pt)	2003-09-26	2008-02-29	Glaxo Group Ltd	Forma polimórfica de 3-fenilsulfonil-8-piperazin-1-il-quinolina
GB0407025D0 (en)	2004-03-29	2004-04-28	Glaxo Group Ltd	Novel compounds
GB0411421D0 (en)	2004-05-21	2004-06-23	Glaxo Group Ltd	Novel compounds
GB0422263D0 (en)	2004-10-07	2004-11-10	Glaxo Group Ltd	Novel compounds
GB0519760D0 (en)	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds
GB0519758D0 (en)	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel process
GB0519765D0 (en)	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds

2003
- 2003-03-25 ES ES08157490T patent/ES2386828T3/es not_active Expired - Lifetime
- 2003-03-25 PT PT08157490T patent/PT1956004E/pt unknown
- 2003-03-25 DK DK03714889T patent/DK1497266T3/da active
- 2003-03-25 TW TW092106558A patent/TWI268928B/zh not_active IP Right Cessation
- 2003-03-25 AT AT03714889T patent/ATE398108T1/de active
- 2003-03-25 IL IL16410803A patent/IL164108A0/xx unknown
- 2003-03-25 DE DE60321558T patent/DE60321558D1/de not_active Expired - Lifetime
- 2003-03-25 US US10/509,078 patent/US7452888B2/en not_active Expired - Lifetime
- 2003-03-25 WO PCT/EP2003/003197 patent/WO2003080580A2/en not_active Ceased
- 2003-03-25 NZ NZ535239A patent/NZ535239A/en not_active IP Right Cessation
- 2003-03-25 RU RU2004131641/04A patent/RU2309154C9/ru not_active IP Right Cessation
- 2003-03-25 AU AU2003219103A patent/AU2003219103B2/en not_active Ceased
- 2003-03-25 BR BRPI0308696A patent/BRPI0308696B8/pt not_active IP Right Cessation
- 2003-03-25 MX MXPA04009318A patent/MXPA04009318A/es active IP Right Grant
- 2003-03-25 SI SI200331326T patent/SI1497266T1/sl unknown
- 2003-03-25 JP JP2003578335A patent/JP4455064B2/ja not_active Expired - Fee Related
- 2003-03-25 MY MYPI20031054A patent/MY138836A/en unknown
- 2003-03-25 CN CNB038116448A patent/CN1315809C/zh not_active Expired - Fee Related
- 2003-03-25 KR KR1020047015297A patent/KR101020399B1/ko not_active Expired - Fee Related
- 2003-03-25 PT PT03714889T patent/PT1497266E/pt unknown
- 2003-03-25 DK DK08157490.7T patent/DK1956004T3/da active
- 2003-03-25 AR ARP030101028A patent/AR039127A1/es not_active Application Discontinuation
- 2003-03-25 EP EP03714889A patent/EP1497266B1/en not_active Expired - Lifetime
- 2003-03-25 SI SI200332178T patent/SI1956004T1/sl unknown
- 2003-03-25 EP EP08157490A patent/EP1956004B1/en not_active Expired - Lifetime
- 2003-03-25 ES ES03714889T patent/ES2307919T3/es not_active Expired - Lifetime
- 2003-03-25 CA CA2479786A patent/CA2479786C/en not_active Expired - Fee Related
- 2003-03-25 PL PL374378A patent/PL209872B1/pl unknown
2004
- 2004-09-13 ZA ZA2004/07320A patent/ZA200407320B/en unknown
- 2004-09-14 IL IL164108A patent/IL164108A/en not_active IP Right Cessation
- 2004-09-24 IS IS7470A patent/IS2599B/is unknown
- 2004-10-25 NO NO20044588A patent/NO329319B1/no not_active IP Right Cessation
2008
- 2008-09-03 CY CY20081100943T patent/CY1108313T1/el unknown
- 2008-09-05 US US12/205,079 patent/US7601837B2/en not_active Expired - Fee Related
2009
- 2009-05-25 JP JP2009125459A patent/JP5091913B2/ja not_active Expired - Fee Related
- 2009-08-14 US US12/541,456 patent/US7799774B2/en not_active Expired - Fee Related
2010
- 2010-07-30 US US12/847,039 patent/US7977337B2/en not_active Expired - Fee Related
2011
- 2011-06-03 US US13/152,356 patent/US8236947B2/en not_active Expired - Fee Related
2012
- 2012-09-05 CY CY20121100804T patent/CY1113306T1/el unknown

Also Published As

Publication number	Publication date
TW200403224A (en)	2004-03-01
MXPA04009318A (es)	2005-01-25
HK1074439A1 (en)	2005-11-11
ES2307919T3 (es)	2008-12-01
IL164108A0 (en)	2005-12-18
PL209872B1 (pl)	2011-10-31
NO329319B1 (no)	2010-09-27
BRPI0308696A8 (pt)	2017-04-11
ATE398108T1 (de)	2008-07-15
US20110237792A1 (en)	2011-09-29
CY1113306T1 (el)	2016-04-13
JP2005531518A (ja)	2005-10-20
WO2003080580A3 (en)	2004-02-05
AU2003219103B2 (en)	2008-10-23
AU2003219103A1 (en)	2003-10-08
SI1956004T1 (sl)	2012-09-28
JP2009235080A (ja)	2009-10-15
CA2479786A1 (en)	2003-10-02
ZA200407320B (en)	2005-11-30
IL164108A (en)	2010-05-31
EP1956004A1 (en)	2008-08-13
DK1497266T3 (da)	2008-10-06
BRPI0308696B1 (pt)	2019-07-16
AR039127A1 (es)	2005-02-09
US7977337B2 (en)	2011-07-12
TWI268928B (en)	2006-12-21
NO20044588L (no)	2004-10-25
US7452888B2 (en)	2008-11-18
JP4455064B2 (ja)	2010-04-21
US8236947B2 (en)	2012-08-07
RU2309154C2 (ru)	2007-10-27
US7799774B2 (en)	2010-09-21
CN1656075A (zh)	2005-08-17
KR20040094874A (ko)	2004-11-10
MY138836A (en)	2009-07-31
US20090298841A1 (en)	2009-12-03
KR101020399B1 (ko)	2011-03-08
CN1315809C (zh)	2007-05-16
ES2386828T3 (es)	2012-08-31
EP1956004B1 (en)	2012-06-13
PT1497266E (pt)	2008-09-10
US7601837B2 (en)	2009-10-13
CA2479786C (en)	2011-11-29
NZ535239A (en)	2008-03-28
US20090036682A1 (en)	2009-02-05
WO2003080580A2 (en)	2003-10-02
PL374378A1 (en)	2005-10-17
RU2309154C9 (ru)	2016-09-27
US20100305107A1 (en)	2010-12-02
IS7470A (is)	2004-09-24
BR0308696A (pt)	2005-01-25
BRPI0308696B8 (pt)	2021-05-25
DK1956004T3 (da)	2012-08-06
EP1497266B1 (en)	2008-06-11
CY1108313T1 (el)	2014-02-12
SI1497266T1 (sl)	2008-10-31
US20050124628A1 (en)	2005-06-09
EP1497266A2 (en)	2005-01-19
PT1956004E (pt)	2012-08-31
DE60321558D1 (de)	2008-07-24
RU2004131641A (ru)	2005-06-27
JP5091913B2 (ja)	2012-12-05

Publication	Publication Date	Title
IS2599B (is)	2010-04-15	3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
NO2022041I1 (no)	2022-10-03	Dapagliflozin og farmasøytisk akseptable salter derav - forlenget SPC
IS2504B (is)	2009-04-15	Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
LUC00127I2 (fr)	2020-10-06	Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
LU92517I2 (fr)	2014-10-13	Delamanide et ses dérivés pharmaceutiquement acceptables
NO20041975D0 (no)	2004-05-13	Bicyklisk oksopyridin og oksopyrimidinderivater
IS6385A (is)	2002-05-15	Ný notkun og nýjar N-asabísýkló-amíð afleiður
DE60319951D1 (de)	2008-05-08	Aminocyclische substituierte pyrrolopyrimidinderivate und pyrrolopyridinderivate
LU92513I2 (fr)	2015-11-02	Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
ATE478870T1 (de)	2010-09-15	Spiroindolinpiperidinderivate
ATE460418T1 (de)	2010-03-15	Heterocyclocarboxamidderivate
DK1551802T3 (da)	2010-03-15	Indol-3-svovlderivater
ATE467631T1 (de)	2010-05-15	Chinuclidinamidderivate
IS7720A (is)	2005-03-01	Píperidín-N-oxíð-afleiður
DK2248807T3 (da)	2013-08-26	N-Phenyl-2-pyrimidinaminderivater
IS6934A (is)	2003-08-29	Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20052524D0 (no)	2005-05-26	Aminerte isofiavonoidderivater og anvendelse derav
DK1513835T3 (da)	2006-12-27	Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1590321T3 (da)	2010-08-09	Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
ATE335729T1 (de)	2006-09-15	3h-chinazoline -4-on derivaten
DK1525193T3 (da)	2008-04-28	Acylaminothiazolderivater, deres fremstilling og deres terapeutiske anvendelse
DK1556382T3 (da)	2008-10-06	3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
ATE423771T1 (de)	2009-03-15	Tetrahydrochinolinderivate
DE50306277D1 (de)	2007-02-22	4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
ATE299873T1 (de)	2005-08-15	Substituierte c-furan-2-yl-methylamin- und c- thiophen-2-yl-methylamin-derivate